The size of the Non-Invasive Prenatal Testing Market was valued at USD 0.47 Billion in 2021. It is further projected to be growing at a CAGR of 20.3% and worth USD 1.18 billion by 2026.
During pregnancy, fetal DNA is freely circulating through the mother’s blood and is known as cell-free DNA (cf-DNA). The analysis of this cf-DNA is one of the methods of Non-Invasive Prenatal Testing.
Non-Invasive Prenatal Testing, also known as Non-Invasive Prenatal Screening, is the latest development in genetic testing that screens a mother’s blood during pregnancy and accurately identify the most common genetic disorders Syndrome, Patau Syndrome, and Edward Syndrome. Among its other uses is the gender determination of a baby.
The growth of the Asia-Pacific Non-Invasive Prenatal Testing Market is mainly driven by factors such as the high prevalence of genetic disorders distributed in a huge population base, growing awareness about genetic abnormalities, leaps in technological advancements, and the customer preference for non-invasive techniques over invasive ones. Low clinical validity of Non-Invasive Prenatal Testing results is one of the major constraints of the market.
This research report on the Asia Pacific Non-Invasive Prenatal Testing Market has been segmented and sub-segmented into the following categories.
By Instruments:
By Method:
By Application:
By End User:
By Country:
Key players operating in the Asia Pacific Non-Invasive Prenatal Testing Market profiled in this report are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Instruments
5.1.1 Introduction
5.1.2 PCR
5.1.3 Ultrasound
5.1.4 NGS
5.1.5 Microarray
5.1.6 Y-o-Y Growth Analysis, By Instruments
5.1.7 Market Attractiveness Analysis, By Instruments
5.1.8 Market Share Analysis, By Instruments
5.2 Method
5.2.1 Introduction
5.2.2 FCMB
5.2.3 Cell-Free DNA (cf-DNA)
5.2.4 Y-o-Y Growth Analysis, By Method
5.2.5 Market Attractiveness Analysis, By Method
5.2.6 Market Share Analysis, By Method
5.3 Application
5.3.1 Introduction
5.3.2 Trisomy
5.3.3 Microdeletion
5.3.4 Genetics
5.3.5 Rh factor
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End User
5.4.1 Introduction
5.4.2 Hospital
5.4.3 Diagnostic Labs
5.4.4 Y-o-Y Growth Analysis, By End User
5.4.5 Market Attractiveness Analysis, By End User
5.4.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Instruments
6.1.3.3 By Method
6.1.3.4 By Application
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Instruments
6.1.4.3 By Method
6.1.4.4 By Application
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Instruments
6.1.5.3 By Method
6.1.5.4 By Application
6.1.5.5 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Koninklijke Philips N.V
8.3 Thermo Fisher Scientific
8.4 Hoffman-La Roche
8.5 Pacific Biosciences of California
8.6 PerkinElmer
8.7 QIAGEN N.V
8.8 Agilent Technologies
8.9 Beijing Genomics Institute
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
